Hims & Hers Health’s third quarter results prompted a positive market reaction as the company delivered strong revenue growth ...

Although Hims & Hers Health has tanked in the past month, the quantitative profile suggests a contrarian trade is brewing for ...

Wondering if Hims & Hers Health is a hidden value gem or already fairly priced? You're not alone, as plenty of investors are sizing up its potential in today's dynamic market. The stock is no stranger ...

Hims & Hers Health ($HIMS) stock has been a wild ride lately, as investors struggle to decide whether it’s the future of ...

Hims & Hers delivered yet another strong quarter of revenue growth in Q3, with sales climbing 49% year over year to $599 ...

The acquisition will unlock a new level of personalized healthcare and deliver integrated offerings across nutrition, lifestyle, supplements, and medication SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers ...

Q3 2025 Management View CEO Andrew Dudum stated the company's strategy is "expanding reach, deepening engagement and ...

Investors considering a purchase of Hims & Hers Health Inc (Symbol: HIMS) shares, but tentative about paying the going market price of $42.06/share, might benefit from considering selling puts among ...

-- Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to ...

Shares of telehealth company Hims & Hers Health got a boost last week on news that it will start offering popular weight-loss drug Wegovy. Founded in 2017, Hims & Hers is a direct-to-consumer ...

Hims & Hers Health announced Wednesday it has acquired New Jersey-based at-home lab testing facility Trybe Labs. The deal will allow the telehealth company to offer at-home blood draws and more ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...